Tubercular Meningitis in Children: Case Discussion & Key Learning Points
Model Case Presentation
Patient Demographics
Name: Master Arjun, Age: 4 years, Gender: Male, Informant: Mother (Reliable)
Chief Complaints
- Fever — 3 weeks
- Headache and vomiting — 10 days
- Altered sensorium — 3 days
History Summary
Insidious onset of low-grade fever for 3 weeks, associated with loss of appetite, weight loss, and behavioral change (irritability, lethargy). Subsequently developed persistent headache, projectile vomiting (not related to feeds), and neck pain. For the last 3 days, the child has become drowsy with decreased responsiveness. One episode of generalized tonic-clonic seizure 2 days ago.
Contact history: Father has pulmonary tuberculosis diagnosed 2 months ago, currently on ATT. BCG scar present. No prior history of TB. Not vaccinated against Haemophilus influenzae or meningococcus. Born at term, NVD, normal developmental milestones until illness. Non-consanguineous parents, no family history of neurological disease.
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Temperature | 38.6°C | Low-grade fever — subacute course |
| GCS | E3V4M5 = 12 | Stage II TBM (BMRC) |
| Weight | 12 kg (below 3rd centile) | Malnutrition / wasting |
| HR | 106/min | Mild tachycardia |
| BP | 100/60 mmHg | Normal (Cushing's triad absent) |
| Pupils | Right > Left (anisocoria) | Possible CN III palsy / herniation |
Meningeal signs: Neck rigidity present. Kernig's sign positive bilaterally. Brudzinski's sign positive.
Cranial nerves: Right lateral rectus palsy (CN VI — most common in TBM). Mild papilledema on fundoscopy.
Other findings: No rash. Spleen tip palpable (2 cm). Mild hepatomegaly. No lymphadenopathy. Chest: crepitations at left upper zone.
✅ Complete Diagnosis
Tuberculous Meningitis (Stage II, BMRC) with Raised Intracranial Pressure and Left-Sided Cranial Nerve VI Palsy, in a child with known household TB contact, malnutrition, and probable pulmonary TB (left upper zone infiltrate).
📝 History — Exam Q&A
Tuberculous meningitis (TBM) is the most common and most severe form of CNS tuberculosis. It accounts for approximately 1% of all TB cases but causes disproportionate mortality and morbidity — death or severe disability occurs in up to 50% of those affected despite treatment.
TBM predominantly affects children under 5 years of age, with peak incidence between 6 months and 4 years. Young children are at higher risk because their immune systems (cell-mediated immunity) are immature and they cannot effectively contain primary TB infection, leading to hematogenous dissemination to the CNS.
TBM develops in two stages:
- Stage 1 — Seeding: After primary pulmonary infection, Mycobacterium tuberculosis (MTB) disseminates hematogenously and seeds the meninges or brain parenchyma, forming subependymal foci called Rich foci.
- Stage 2 — Rupture: These Rich foci later rupture into the subarachnoid space, triggering an intense inflammatory exudate — primarily at the base of the brain (basilar exudate). This causes:
- Basal meningeal inflammation → cranial nerve palsies
- Vasculitis → cerebral infarction
- Obstruction of CSF flow → hydrocephalus
💡 Rich Focus
The Rich focus (described by Arnold Rich, 1933) is the subependymal caseous granuloma that ruptures to cause TBM. This is why there is usually a lag between primary infection and TBM onset.
| Phase | Duration | Features |
|---|---|---|
| Stage I — Prodromal (non-specific) | 1–3 weeks | Low-grade fever, malaise, irritability, headache, loss of appetite, weight loss, behavioral change. No neurological signs. |
| Stage II — Meningitic | Days to weeks | Prominent meningeal signs (neck rigidity, Kernig's, Brudzinski's), headache, vomiting, lethargy, cranial nerve palsies, mild altered sensorium. |
| Stage III — Encephalitic (Paralytic) | Late | Stupor, coma, decerebrate posturing, hemiplegia, dense cranial nerve palsies, seizures, Cheyne-Stokes breathing. Imminent death without treatment. |
This clinical staging corresponds to the British Medical Research Council (BMRC) staging system.
| Stage | GCS | Neurological Features | Prognosis |
|---|---|---|---|
| Stage I | GCS 15 | No focal deficit, no altered consciousness | Good (~90% survival without deficit) |
| Stage II | GCS 11–14, OR GCS 15 with focal deficit | Cranial nerve palsy, mild confusion, focal deficit | Moderate (~50–70% good outcome) |
| Stage III | GCS < 10 | Coma, hemiplegia, decerebrate posturing | Poor (mortality > 50%) |
Stage at presentation is the single strongest predictor of outcome. Early diagnosis (Stage I) is key.
- Contact history: Close contact with an adult with active pulmonary TB (most important risk factor in children)
- Duration of fever: TBM fever is subacute — >5 days to weeks (helps distinguish from acute bacterial meningitis)
- Prodromal symptoms: Irritability, behavioral change, anorexia preceding neurological symptoms
- Headache character: Progressive, positional (worsens on lying flat — raised ICP)
- Vomiting: Projectile, not related to feeds — raised ICP
- Seizures: Type, frequency — common in children with TBM (~50% pediatric cases)
- BCG vaccination status: BCG reduces risk of severe forms of TB including TBM by 70–80%
- Prior TB treatment: Drug resistance risk
- HIV status: Immunosuppression increases risk and modifies presentation
- Malnutrition: Key risk factor for progression to severe disease
Young children have immature cell-mediated immunity (CMI). When exposed to an infectious adult source (smear-positive pulmonary TB), they develop primary TB. Unlike adults, who can contain the infection in pulmonary lymph nodes, young children are prone to primary progressive disease — the primary complex rapidly disseminates hematogenously, seeding the meninges. The risk of TBM after primary infection is:
- ~5% in children under 1 year
- ~2–3% in children 1–5 years
- Much lower in older children and adults
Hence, contact tracing and isoniazid preventive therapy (IPT) in exposed young children is a critical public health strategy.
| Feature | TBM | Bacterial Meningitis |
|---|---|---|
| Onset | Insidious (days to weeks) | Acute (hours to 2 days) |
| Fever duration before diagnosis | >5–7 days (often 2–3 weeks) | <3 days |
| Prodrome | Yes — irritability, weight loss, anorexia | Usually no prodrome |
| Seizures (children) | Common (~50%) | Less common (~20–30%) |
| Cranial nerve palsy | Common (CN VI, III, VII) | Uncommon |
| TB contact | Often present | Absent |
| Rash | Absent | Petechiae/purpura (meningococcal) |
🩺 Examination — Exam Q&A
- Neck rigidity (Nuchal rigidity): Resistance to passive flexion of the neck with hips extended. Due to meningeal irritation.
- Kernig's sign: With the patient supine and hip flexed to 90°, extension of the knee beyond 135° is painful/resisted due to meningeal irritation along the lumbar nerve roots. Positive = restricted extension with pain.
- Brudzinski's sign: Passive flexion of the neck causes involuntary flexion of both knees and hips. Due to reflex protective response to meningeal irritation.
💡 Important Caveat
In infants <12–18 months, meningeal signs may be absent even in severe meningitis. Bulging fontanelle, high-pitched cry, and opisthotonus are more reliable in this age group.
CN VI (Abducens nerve) is the most commonly affected cranial nerve in TBM. It causes lateral rectus palsy — the eye deviates medially with failure of lateral gaze. This is a false localizing sign of raised intracranial pressure — the CN VI has the longest intracranial course and is stretched by raised ICP.
Other cranial nerves affected in TBM (in order of frequency): CN VI > CN III > CN VII > CN IV > CN II (optic).
CN III palsy presents with ptosis, dilated pupil, "down and out" eye. CN VII palsy causes ipsilateral lower motor neuron facial weakness.
- Headache: Severe, progressive, worse on lying down / Valsalva
- Vomiting: Projectile, not related to feeds
- Papilledema: Bilateral disc swelling (takes 24–48 hours to develop)
- CN VI palsy: False localizing sign
- Sunset sign: Eyes deviate downward (in infants — also seen with hydrocephalus)
- Bulging fontanelle: In infants
- Cushing's triad (late): Hypertension + Bradycardia + Irregular respiration — impending herniation
- Altered sensorium
🚨 LP Safety
Perform CT scan before LP if there are signs of RICP (papilledema, focal deficits, GCS <12) to rule out a mass lesion and prevent herniation.
- Papilledema — bilateral disc edema with blurred margins (raised ICP)
- Choroidal tubercles — small, pale-yellow, discrete, avascular lesions seen in the choroid; pathognomonic of miliary/disseminated TB. Present in ~10–30% of TBM cases with miliary TB.
- Optic atrophy — late complication; indicates prolonged pressure on optic nerve
Choroidal tubercles, when found, are very specific and confirm disseminated TB — they do not require biopsy.
- Rapidly increasing head circumference (macrocephaly)
- Bulging, tense anterior fontanelle
- Sunset sign — downward gaze deviation of eyes (setting sun appearance) due to pressure on superior colliculus
- Dilated scalp veins
- High-pitched cry
- Cracked-pot sound on skull percussion (Macewen's sign)
- Irritability and poor feeding
TBM causes hydrocephalus via two mechanisms: (1) communicating — basal exudate blocks CSF reabsorption at arachnoid granulations; (2) non-communicating — exudate obstructs the aqueduct of Sylvius or 4th ventricle foramina.
BCG vaccine provides 70–80% protection against the severe forms of TB — particularly miliary TB and TBM — in children. The presence of a BCG scar:
- Reduces but does not eliminate the risk of TBM
- May modify the clinical presentation (milder, slower course)
- Does not protect against pulmonary TB in adults
Absence of BCG scar in a child from a TB-endemic country is a significant risk factor for developing TBM after primary infection.
Motor signs in TBM arise from vasculitic infarction or direct compression:
- Hemiplegia / hemiparesis: Due to infarction in MCA/ACA territory from TB vasculitis; internal capsule is a common site
- Quadriplegia: Bilateral infarctions or brainstem involvement
- Decerebrate posturing: Extension of all limbs — severe brainstem compression/Stage III disease
- Decorticate posturing: Flexion of arms, extension of legs — cortical injury
- Diplegia: Can occur from hydrocephalus-related white matter damage
- Cerebellar signs: Ataxia — if posterior fossa involved
- Choroidal tubercles on fundoscopy (pathognomonic)
- Hepatosplenomegaly (miliary seeding of liver/spleen)
- Lymphadenopathy (generalized or cervical)
- Skin papules or nodules (rare)
- Chest signs — bilateral crepitations (miliary pattern on CXR)
- Failure to thrive / severe malnutrition
About 50–60% of children with TBM have evidence of extra-neural TB, most commonly miliary or pulmonary TB. Identifying extra-neural TB significantly aids clinical diagnosis.
🔬 Investigations — Exam Q&A
| Parameter | TBM Finding | Normal / Reference |
|---|---|---|
| Appearance | Clear / slightly turbid (cobweb clot on standing) | Crystal clear |
| Opening pressure | Elevated (usually 200–400 mmH₂O) | <200 mmH₂O |
| Cell count | 50–500 cells/µL (10–500 range) | <5 cells/µL |
| Cell type | Lymphocytic predominance (>50%) | — |
| Protein | Elevated: 100–500 mg/dL (often >100 mg/dL) | <40 mg/dL |
| CSF glucose | Low: <45 mg/dL | 45–80 mg/dL |
| CSF:serum glucose ratio | <0.5 (often <0.3) | >0.5 |
| AFB smear | Positive in 10–40% (low sensitivity) | Negative |
| Culture (LJ medium) | Gold standard; positive in 45–90%; takes 4–8 weeks | Negative |
💡 Cobweb Clot
When CSF from TBM is allowed to stand, a cobweb/pellicle clot forms due to high fibrinogen content. This is characteristic of TBM but not pathognomonic.
| Feature | TBM | Bacterial | Viral |
|---|---|---|---|
| Appearance | Clear/slightly turbid | Turbid/purulent | Clear |
| Cells | 50–500 (lymphocytes) | 1000–10,000+ (neutrophils) | 10–1000 (lymphocytes) |
| Protein | 100–500 mg/dL | 100–500 mg/dL | Normal to mildly elevated |
| Glucose | Low (<45) | Very low (<40) | Normal |
| CSF:serum glucose | <0.5 | <0.4 | >0.5 |
| Chloride | Decreased | Decreased | Normal |
| AFB | +ve in 10–40% | Negative | Negative |
Key differentiator: TBM has lymphocytic pleocytosis with very low glucose and very high protein — a combination that is uncommon in viral meningitis (which has normal glucose). Bacterial meningitis has neutrophilic pleocytosis.
CSF culture on Lowenstein-Jensen (LJ) medium is the gold standard — it is highly specific. However, significant limitations include:
- Takes 4–8 weeks for growth — not useful for acute management
- Sensitivity: 45–90% (paucibacillary nature of TBM)
- Requires large volume CSF (≥5–6 mL), multiple samples increase yield
- Yield improved by centrifugation of CSF before culture
- MGIT (Mycobacterium Growth Indicator Tube) liquid culture gives results faster (1–3 weeks) with higher sensitivity
Because of these limitations, TBM is primarily a clinical diagnosis supported by CSF analysis, neuroimaging, and other TB evidence.
Xpert MTB/RIF Ultra is a rapid nucleic acid amplification test (NAAT) that simultaneously detects MTB DNA and rifampicin resistance within 2 hours. It uses real-time PCR.
Performance in CSF for TBM:
- Sensitivity: ~45–65% (higher than Xpert MTB/RIF; lower than for pulmonary TB due to paucibacillary CSF)
- Specificity: ~98–99%
- Sensitivity is improved by using centrifuged CSF and larger volumes (≥3 mL)
- WHO recommends Xpert Ultra as the initial diagnostic test for CSF (2017 recommendation, updated 2021)
Key limitation: A negative Xpert Ultra does NOT rule out TBM — clinical suspicion must guide treatment initiation.
The classic triad of radiological findings in TBM:
- Basal meningeal enhancement — thickening and contrast enhancement of basal cisterns (suprasellar, sylvian fissures); most characteristic finding
- Hydrocephalus — communicating type most common; dilated lateral and 3rd ventricles
- Cerebral infarction — especially in basal ganglia, internal capsule (lenticulostriate territory) due to TB vasculitis
Additional findings: Tuberculoma (ring-enhancing lesion with central necrosis), periventricular ependymal enhancement.
MRI vs CT: MRI with gadolinium is superior — better for brainstem/posterior fossa, meningeal enhancement, early infarcts, and small tuberculomas. CT is used urgently to assess hydrocephalus (especially before LP) and is more widely available.
ADA is an enzyme produced by T-lymphocytes involved in cellular immunity. Elevated CSF ADA levels reflect T-lymphocyte-mediated inflammation as seen in TBM.
- Cut-off: CSF ADA >10 U/L is suggestive of TBM
- Sensitivity: 44–100%; Specificity: 71–100% (varies by cut-off and study)
- Useful as a rapid, low-cost supportive test when other investigations are unavailable
- Can be falsely elevated in lymphoma, bacterial meningitis
- ADA in pleural fluid (>40 U/L) is also used for diagnosis of tuberculous pleuritis
The Mantoux (tuberculin skin test) involves intradermal injection of 5 TU (tuberculin units) of PPD and reading induration (not erythema) at 48–72 hours.
| Induration | Positive in... |
|---|---|
| ≥5 mm | HIV+, immunocompromised, close TB contact, chest X-ray consistent with old TB |
| ≥10 mm | Children <5 years, children with TB risk factors, immigrants from high-burden countries |
| ≥15 mm | Persons with no risk factors |
Important: In TBM, up to 40–50% of children may have a negative Mantoux due to immunosuppression from severe illness (anergy). A negative result does not exclude TBM.
Developed in 2010 to standardize TBM research definitions. It classifies patients as Definite, Probable, Possible, or Not TBM based on a composite score across four domains:
| Domain | Points Available | Examples |
|---|---|---|
| Clinical criteria | Up to 6 points | Symptoms >5 days, TB contact, fever, neck stiffness, focal deficit, cranial nerve palsy, altered sensorium |
| CSF criteria | Up to 4 points | Lymphocytes 10–500/µL, protein >1 g/L, glucose <2.2 mmol/L, CSF:plasma ratio <0.5 |
| Neuroimaging criteria | Up to 6 points | Hydrocephalus, basal meningeal enhancement, infarction, tuberculoma |
| Evidence of extra-neural TB | Up to 4 points | CXR suggesting TB, CT chest miliary TB, microbiological evidence elsewhere |
Classification: Definite TBM = microbiologically confirmed. Probable TBM = score ≥12 (with imaging) or ≥10 (without imaging). Possible TBM = score 6–11 (with imaging) or 6–9 (without imaging).
- Chest X-ray: Miliary pattern, primary complex (Ghon's focus + enlarged hilar nodes), consolidation — evidence of active pulmonary TB in 50–60%
- Gastric lavage / sputum AFB smear and culture: To isolate MTB and obtain drug sensitivity
- CBC: Lymphocytosis, anemia; ESR elevated
- Serum electrolytes: Hyponatremia common (30–50%) — due to SIADH or cerebral salt wasting
- HIV testing: Mandatory in all suspected TBM cases
- IGRA (Interferon Gamma Release Assay): QuantiFERON-TB Gold — not affected by BCG vaccination; useful in BCG-vaccinated children; does not distinguish latent from active disease
- Fundoscopy: Choroidal tubercles, papilledema
- Ophthalmological examination: Visual acuity (ethambutol monitoring)
- Liver function tests: Baseline before ATT (hepatotoxicity risk)
- Audiometry: Baseline before streptomycin/aminoglycosides
- EEG: If seizures present
💊 Management — Exam Q&A
WHO recommends a 12-month regimen for drug-susceptible TBM in children:
Standard Regimen: 2HRZE / 10HR
Intensive phase (2 months): Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E)
Continuation phase (10 months): Isoniazid (H) + Rifampicin (R)
| Drug | Pediatric Dose | CSF Penetration |
|---|---|---|
| Isoniazid (H) | 10–15 mg/kg/day (max 300 mg) | Excellent (90–100% of serum) |
| Rifampicin (R) | 10–20 mg/kg/day (max 600 mg) | Good with inflamed meninges (10–20%) |
| Pyrazinamide (Z) | 30–40 mg/kg/day (max 2 g) | Excellent (>90%) |
| Ethambutol (E) | 15–25 mg/kg/day (max 1.2 g) | Poor; used for anti-resistance coverage |
Note: Ethionamide is substituted for ethambutol in some guidelines (South Africa's Cape Town regimen) due to better CNS penetration.
Corticosteroids reduce the intense inflammatory response (basilar exudate formation, vasculitis, cerebral edema) that causes much of the damage in TBM. They have been shown to improve survival and reduce neurological sequelae.
WHO recommends corticosteroids for ALL children with TBM (regardless of severity/stage).
| Drug | Dose | Duration |
|---|---|---|
| Prednisolone | 2 mg/kg/day (max 60 mg), may increase to 4 mg/kg/day in severely ill | 4 weeks, then taper over 2–4 weeks |
| Dexamethasone | 0.3–0.6 mg/kg/day (equivalent alternative) | 4–6 weeks, then taper |
Benefits: Reduce cerebral edema, vasculitis, risk of stroke, scarring. Do NOT withhold steroids if initiating empirical ATT in high-suspicion cases.
Hyponatremia occurs in 30–50% of TBM patients, from two different mechanisms that require opposite management:
| Mechanism | SIADH | Cerebral Salt Wasting (CSW) |
|---|---|---|
| Volume status | Euvolemic or hypervolemic | Hypovolemic |
| Urine sodium | High | High (very high) |
| Urine output | Low (concentrated) | High (polyuria) |
| Management | Fluid restriction + correct Na slowly | Normal saline replacement + fludrocortisone |
🚨 Critical Point
SIADH and CSW both cause hyponatremia with high urinary sodium, but have opposite volume status. Misidentification leads to dangerous management errors. Assess clinical hydration and urine output carefully.
Correct sodium slowly — rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome (central pontine myelinolysis). Target correction rate: <10 mEq/L per 24 hours.
Hydrocephalus complicates TBM in 40–85% of pediatric cases and must be managed urgently if severe:
- Communicating hydrocephalus (mild–moderate): Medical treatment — acetazolamide ± furosemide (reduce CSF production); optimize ATT and steroids
- Communicating hydrocephalus (severe/progressive): Ventriculoperitoneal (VP) shunt — surgical diversion of CSF to peritoneum. Risk: shunt blockage (high CSF protein is a risk factor)
- Non-communicating hydrocephalus: Endoscopic Third Ventriculostomy (ETV) — creates a bypass at floor of 3rd ventricle; preferred if aqueductal obstruction is confirmed
- Emergency decompression: External ventricular drain (EVD) as a temporary measure in acute deterioration
Corticosteroids alone may temporarily reduce CSF protein and improve CSF flow.
Seizures occur in ~50% of children with TBM. Management:
- Acute seizure: IV lorazepam or diazepam (first-line)
- Maintenance AED: Levetiracetam (preferred — no hepatic enzyme induction, less drug interaction with rifampicin). Alternatives: valproate, phenobarbitone.
- Avoid phenytoin/carbamazepine where possible — they are hepatic enzyme inducers that accelerate rifampicin metabolism, reducing its efficacy
- Duration: Typically continued for 1–2 years after last seizure, or based on EEG normalization
- Hydrocephalus — most common complication; occurs in 40–85% of pediatric TBM
- Cerebral infarction — from TB vasculitis of perforating arteries; causes hemiplegia, motor deficits
- Epilepsy — post-TBM seizure disorder
- Cranial nerve palsies — CN VI, III, VII palsy; may be permanent
- Intellectual disability / cognitive impairment — especially in young children who survive severe disease
- Hearing loss — sensorineural (from basilar meningitis affecting CN VIII or inner ear); also a side effect of streptomycin/aminoglycosides
- Visual impairment / blindness — optic atrophy from prolonged papilledema or optic chiasm compression
- Behavioral and neuropsychiatric disorders
- Paradoxical reaction — transient clinical worsening 2–8 weeks after starting ATT; due to immune reconstitution; more common in HIV+; managed by continuing ATT ± steroids
IPT (also called TB preventive therapy, TPT) is isoniazid given to individuals with latent TB infection to prevent progression to active disease.
Indications in children:
- Children <5 years who are close contacts of smear-positive pulmonary TB case — regardless of Mantoux result
- Children ≥5 years with positive Mantoux (≥10 mm) or IGRA who have not had active TB ruled out
- HIV-positive children — regardless of Mantoux
Regimen: Isoniazid 10 mg/kg/day (max 300 mg) for 6 months. Alternative: 3HP (isoniazid + rifapentine weekly × 12 weeks) in children ≥2 years.
IPT reduces risk of TBM by up to 70% in high-risk contacts.
| Drug | Important Side Effects | Monitoring |
|---|---|---|
| Isoniazid | Hepatotoxicity, peripheral neuropathy (prevent with pyridoxine B6), seizures (rare) | LFT, give pyridoxine 5–10 mg/day |
| Rifampicin | Hepatotoxicity, orange discoloration of body fluids, enzyme inducer (↓ levels of phenytoin, OCP, corticosteroids, antiretrovirals) | LFT, warn about orange urine |
| Pyrazinamide | Hepatotoxicity (most hepatotoxic of first-line drugs), hyperuricemia, arthralgia | LFT, uric acid |
| Ethambutol | Optic neuritis (retrobulbar) — red-green color vision loss, decreased visual acuity; dose-dependent | Monthly visual acuity and colour vision. Avoid in children <5 years who cannot report visual symptoms |
| Streptomycin | Ototoxicity (irreversible sensorineural hearing loss), nephrotoxicity, vestibular toxicity | Baseline audiometry, renal function. Avoid in pregnancy |
TBM is a clinical emergency — do not delay treatment waiting for culture results (takes 4–8 weeks). Empirical ATT should be started immediately when:
- Clinical picture is consistent with TBM (subacute meningitis + at least one of: TB contact, lymphocytic CSF with low glucose/high protein, positive Mantoux, evidence of extra-neural TB)
- CSF AFB smear or Xpert Ultra is positive
- CSF findings are suggestive and other causes (bacterial, viral, fungal) are unlikely
- Neuroimaging shows typical TBM features
The rule: If the clinical suspicion is strong enough to consider TBM, it is strong enough to start treatment. Early treatment (Stage I) gives the best outcome. Treatment can always be stopped if an alternative diagnosis is confirmed.
🔭 Recent Advances — Exam Q&A
Rifampicin has relatively poor CNS penetration (~10–20% of serum levels). Standard doses may not achieve adequate bactericidal concentrations in CSF. Recent trials have explored high-dose rifampicin:
- TBM-KIDS trial (2022): High-dose rifampicin (30 mg/kg/day) ± levofloxacin vs standard dose in pediatric TBM — suggested improved outcomes with high-dose rifampicin but increased adverse events; was underpowered
- SURE trial (ongoing): Comparing 6-month intensified regimen (rifampicin 30 mg/kg + isoniazid 20 mg/kg + pyrazinamide 40 mg/kg + levofloxacin 20 mg/kg) vs standard 12-month WHO regimen in children
- High-dose rifampicin improves bactericidal activity in animal models and early-phase human studies
Current WHO recommendation remains standard dosing pending definitive trial results.
The Cape Town / South African regimen is a 6-month intensive regimen:
- Isoniazid (15–20 mg/kg/day) + Rifampicin (22.5–30 mg/kg/day) + Pyrazinamide (35–45 mg/kg/day) + Ethionamide (17.5–22.5 mg/kg/day) for 6 months
- Key difference: Ethionamide replaces Ethambutol — ethionamide has excellent CSF penetration (~90%); also has bactericidal activity against MTB in the CNS
- Higher doses of all three primary drugs
This regimen is also endorsed by WHO as an option for pediatric TBM. It is favored in South Africa and some other high-burden settings. Rationale: shorter duration may improve adherence; ethionamide is better suited for CNS disease than ethambutol.
TBM causes hypercoagulable state due to the intense inflammatory response, predisposing to cerebrovascular thrombosis (stroke). Aspirin, as an antiplatelet agent, was studied to reduce stroke risk.
- Rizvi et al.: Aspirin added to ATT significantly reduced stroke risk without increasing adverse events, though did not reduce mortality
- Current evidence supports aspirin's potential in reducing stroke risk in TBM patients
- However, aspirin is not yet a standard recommendation — more large-scale RCTs are needed, especially in children
- Aspirin combined with corticosteroids may have additive anti-inflammatory benefit
mNGS is an untargeted molecular technique that sequences all nucleic acids in a CSF sample and identifies pathogen DNA/RNA by comparing sequences against a reference database.
Advantages in TBM:
- Can detect MTB even in very small quantities (paucibacillary CSF)
- Simultaneously detects other CNS pathogens — useful when the diagnosis is unclear
- Can identify drug resistance mutations
- Turnaround time: 24–72 hours (faster than culture)
- Sensitivity in TBM: ~70–85% (higher than Xpert Ultra in some studies)
Limitations: Very expensive, requires specialized bioinformatics expertise, not widely available in low-resource settings. Currently a research/reference tool, not routine clinical practice.
Both procedures divert CSF to treat hydrocephalus in TBM:
| Feature | ETV | VP Shunt |
|---|---|---|
| Mechanism | Creates an opening at the floor of 3rd ventricle to bypass aqueductal obstruction | Silicone tube diverts CSF from lateral ventricle to peritoneum |
| Best for | Non-communicating hydrocephalus | Communicating hydrocephalus (most TBM) |
| Advantage | No foreign body; no infection risk | Effective for communicating hydrocephalus |
| Disadvantage | Less effective if high CSF protein; not ideal for communicating type | Shunt blockage common (high CSF protein clog); requires revision. Blockage rate ~27% in pediatric TBM |
Before VP shunt: Reduce CSF protein with optimal ATT + steroids to minimize blockage risk.
The Tuberculous Meningitis International Research Consortium published the first comprehensive international clinical practice guideline for TBM in the Lancet Infectious Diseases (August 2025). Key points:
- Xpert Ultra recommended as the initial CSF diagnostic test for TBM (strong recommendation)
- Standard WHO regimen (2RHZE/10RH) remains the recommended treatment for drug-susceptible TBM
- Corticosteroids (dexamethasone or prednisolone) recommended for all patients with TBM regardless of HIV status
- Highlights substantial evidence gaps — need for prospective trials, especially in children
- Emphasizes early treatment initiation based on clinical suspicion, even without microbiological confirmation
- Provides guidance on neurocritical care, hydrocephalus management, and paradoxical reactions
⚡ Key Points — Quick Revision
One-Liners for Exam
- Most common CNS TB: Tuberculous meningitis (TBM)
- Peak age: Under 5 years; most dangerous under 1 year
- Pathogenesis: Rupture of Rich focus (subependymal caseous granuloma) into subarachnoid space
- Most important risk factor in children: Household contact with smear-positive pulmonary TB
- BCG vaccine: Protects 70–80% against TBM — reduces but does not eliminate risk
- Clinical phases: Prodromal (non-specific) → Meningitic → Encephalitic/Paralytic
- BMRC Staging: I = GCS 15, no deficit; II = GCS 11–14 or focal deficit; III = GCS <10 / coma
- Most common cranial nerve affected: CN VI (abducens) — lateral rectus palsy, false localizing sign
- CSF: Lymphocytic pleocytosis (50–500 cells) + High protein (>100 mg/dL) + Low glucose (CSF:serum <0.5) + Clear/slightly turbid
- Cobweb clot: Characteristic but not pathognomonic of TBM
- Gold standard: CSF culture on LJ medium (takes 4–8 weeks; sensitivity 45–90%)
- Rapid diagnosis: Xpert MTB/RIF Ultra (sensitivity ~45–65% in CSF; specificity ~99%)
- Neuroimaging triad: Basal meningeal enhancement + Hydrocephalus + Cerebral infarction
- Choroidal tubercles: Pathognomonic of miliary/disseminated TB on fundoscopy
- Hyponatremia causes: SIADH (fluid restrict) vs Cerebral Salt Wasting (fluid replace) — differentiate by volume status
- Standard treatment: 2HRZE / 10HR (12 months total)
- Adjunct treatment: Corticosteroids for ALL children with TBM (dexamethasone 0.3–0.6 mg/kg/day or prednisolone 2–4 mg/kg/day × 4–6 weeks then taper)
- Best CNS-penetrating drugs: Isoniazid > Pyrazinamide > Rifampicin > Ethambutol (poor)
- Ethionamide: Substituted for ethambutol in Cape Town regimen — excellent CNS penetration
- Hydrocephalus Rx: Communicating → VP shunt; Non-communicating → ETV
- Ethambutol side effect: Optic neuritis — avoid in children <5 years
- Isoniazid side effect: Peripheral neuropathy — prevent with pyridoxine (Vit B6)
- IPT: Isoniazid 10 mg/kg/day × 6 months — given to all children <5 years with TB contact
- Negative Mantoux: Does NOT rule out TBM — up to 50% of children may be anergic
- Mortality/disability: 50% death or severe disability even with treatment
- Paradoxical reaction: Worsening 2–8 weeks after starting ATT — continue ATT ± steroids
💡 High-Yield Exam Traps
- Meningeal signs can be absent in infants — always do LP if TBM suspected in a young infant with fever + altered sensorium
- Start ATT empirically if suspicion is high — do not wait for culture
- A negative Xpert Ultra does NOT rule out TBM
- Phenytoin/carbamazepine reduces rifampicin efficacy — prefer levetiracetam for seizures
- Rifampicin turns urine/body fluids orange — warn parents; soft contact lenses may be permanently stained
- Ethambutol is avoided in children <5 years (cannot self-report visual changes)